ACETO Reports Record Fiscal 2013 Third Quarter Net Sales and Gross Profit
FISCAL 2013 THIRD QUARTER HIGHLIGHTS (Comparisons to FY 2012 Q3):
- Net sales increased 24.3% to $150.9 million, a record level
- Gross profit increased 42.3% to $31.5 million, a record level
- Non-GAAP net income increased 92.3% to $9.3 million
- Reported GAAP net income increased 41.2% to $7.6 million
- Non-GAAP EPS increased 88.9% to $0.34
- Reported GAAP EPS increased 40.0% to $0.28
PORT WASHINGTON, N.Y., May 9, 2013 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, announced today results of operations for its fiscal 2013 third quarter and nine months ended March 31, 2013.
Sal Guccione, Chief Executive Officer of ACETO, stated, "We are very pleased with the results achieved in the fiscal third quarter, reporting new records for net sales and gross profit. For the first nine months of fiscal 2013, net sales were up 12.9%. In the fiscal third quarter, our sales growth was attributable to a very strong showing from our Pharmaceutical Ingredients segment, with 52.2% year-over-year growth, primarily driven by demand for a product launch as well as strong performance of various pharmaceutical intermediates. Our Human Health segment was also strong, with sales up 28.8%, compared to last year's third quarter. Recent product launches from Rising Pharmaceuticals fueled the segment's growth. Performance Chemicals' third quarter sales were essentially flat with the comparable quarter in fiscal 2012."
"Our reported earnings per share increased 40.0% on a diluted basis to $0.28. On a non-GAAP basis, EPS increased 88.9% from last year's quarter to $0.34. The non-GAAP adjustment accounts for a $2.8 million charge taken in the third quarter for additional accrued contingent consideration related to the Rising acquisition. The acquisition structure has an earn-out provision based on performance, and Rising has exceeded projections."
"We are pleased with the quarter's performance, but do not expect a repeat in the fiscal 2013 fourth quarter. Our current expectations are for a quarter much more in line with recent historical performance, with our usual caveat that results could vary on a quarterly basis due to the nature of our business and timing of our orders. As a result of our strong fiscal third quarter earnings, we increased our cash position, decreased our borrowings and further improved our balance sheet. We remain committed to investing in our internal growth initiatives and to pursuing strategic acquisitions," concluded Mr. Guccione.
Net sales for the fiscal 2013 third quarter ended March 31, 2013 were $150.9 million, a 24.3% increase from $121.4 million for the fiscal 2012 third quarter. Gross profit for the fiscal 2013 third quarter was $31.5 million, up from gross profit of $22.2 million in the prior year period. Selling, general and administrative expense was $19.8 million in fiscal 2013 third quarter, up 35.7% from the same period 2012. The SG&A increase was primarily related to the $2.8 million charge for additional accrued contingent consideration related to the Rising acquisition as Rising has outperformed expectations, increased research and development expenses at Rising and increased accrued performance awards expense due to overall Company performance. ACETO reported net income of $7.6 million in the quarter, or $0.28 per diluted share, compared to $5.4 million, or $0.20 per diluted share, in the prior year period. The fiscal 2013 third quarter SG&A and, therefore, profits were impacted by the $2.8 million charge for additional accrued contingent consideration related to the Rising acquisition. After adjusting for this charge, ACETO's non-GAAP net income for the fiscal 2013 third quarter was $9.3 million, or $0.34 per share.
Net sales for the nine month period ended March 31, 2013 were $376.6 million, a 12.9% increase from $333.4 million for the nine month period ended March 31, 2012. Gross profit for the fiscal 2013 nine months was $73.7 million, an increase of 20.3%, compared to gross profit of $61.3 million in the prior year period. Selling, general and administrative expense was $47.8 million for the nine months ended March 31, 2013, up 14.6% from the same period 2012. For the nine month period ended March 31, 2013, ACETO reported net income of $16.9 million, or $0.62 per diluted share, compared to $13.0 million, or $0.49 per diluted share, in the prior year period. Net income in the nine month period ended March 31, 2013 increased by 30.2% and earnings per share increased by 26.5%, compared to the comparable fiscal 2012 period. For the first nine months of fiscal 2013, the additional accrued contingent consideration related to the Rising acquisition was $2.8 million. After adjusting for this charge, ACETO's non-GAAP net income for the first nine months was $18.7 million, or $0.68 per share.
At March 31, 2013, cash and cash equivalents and short-term investments were $37.1 million, working capital is $137.3 million and shareholders' equity was $185.2 million.
The Company will conduct a conference call at 9:00 a.m. ET on May 10, 2013 to discuss the operating results for the fiscal 2013 third quarter. Interested parties may participate in the call by dialing 800-447-0521 (847-413-3238 for international callers) – please call in 10 minutes before the call is scheduled to begin, and ask for the ACETO call (conference ID # 34657188). The conference call will also be webcast live via the Investor Relations section of our website, www.aceto.com. To listen to the live call please go to the website at least 15 minutes early to register, download and install any necessary audio software. The conference call will be archived on the Company's website, and a recorded phone replay will also be available from 11:30 a.m. ET on Friday, May 10, 2013 until 5:00 p.m. ET on Monday, May 13, 2013. Dial 888-843-7419 (630-652-3042 for international callers) and enter the code 34657188# for the phone replay.
ACETO Corporation, incorporated in 1947, is a global leader in the marketing, sale and distribution of products for Human Health (finished dosage form generics and nutraceutical products), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products). With business operations in nine countries, ACETO distributes over 1,100 chemical compounds used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical industries. ACETO's global operations, including a staff of 25 in China and 12 in India, are distinctive in the industry and enable its worldwide sourcing and regulatory capabilities.
FORWARD LOOKING STATEMENTS
This news release contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking statements contained in this news release may not occur. Generally, these statements relate to our business plans or strategies, projected or anticipated benefits or other consequences of ACETO's plans or strategies, financing plans, projected or anticipated benefits from acquisitions that ACETO may make, or a projection involving anticipated revenues, earnings or other aspects of ACETO's operating results or financial position, and the outcome of any contingencies. Any such forward-looking statements are based on current expectations, estimates and projections of management. ACETO intends for these forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "project," "plan," "intend," "estimate," and "continue," and their opposites and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained in this press release include, but are not limited to, statements regarding the Company's strategic initiatives including selling finished dosage form generic drugs, and statements regarding the prospects for long-term growth. ACETO cautions you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond ACETO's control, which may influence the accuracy of the statements and the projections upon which the statements are based. Factors that could cause actual results to differ materially from those set forth or implied by any forward-looking statement include, but are not limited to, risks and uncertainties discussed in ACETO's reports filed with the Securities and Exchange Commission, including, but not limited to, ACETO's Annual Report or Form 10-K for the fiscal year ended June 30, 2012 and other filings. Copies of these filings are available at www.sec.gov.
Any one or more of these uncertainties, risks and other influences could materially affect ACETO's results of operations and whether forward-looking statements made by ACETO ultimately prove to be accurate. ACETO's actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. ACETO undertakes no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.
|Aceto Corporation and Subsidiaries|
|Consolidated Statements of Income|
|(in thousands, except per share amounts)|
|Three Months Ended||Nine Months Ended|
|March 31,||March 31,|
|Net sales||$ 150,871||$ 121,415||$ 376,575||$ 333,439|
|Cost of sales||119,344||99,260||302,835||272,121|
|Gross profit %||20.90%||18.25%||19.58%||18.39%|
|Selling, general and administrative expenses||19,781||14,581||47,769||41,678|
|Other (expense) income, net of interest expense||(159)||(26)||336||(189)|
|Income before income taxes||11,587||7,548||26,307||19,451|
|Income tax provision||3,994||2,169||9,381||6,451|
|Net income||$ 7,593||$ 5,379||$ 16,926||$ 13,000|
|Net income per common share||$ 0.28||$ 0.20||$ 0.63||$ 0.49|
|Diluted net income per common share||$ 0.28||$ 0.20||$ 0.62||$ 0.49|
|Weighted average shares outstanding:|
|Aceto Corporation and Subsidiaries|
|Consolidated Balance Sheets|
|(in thousands, except per-share amounts)|
|March 31, 2013||June 30, 2012|
|Cash and cash equivalents||$ 35,423||$ 24,862|
|Trade receivables: less allowances for doubtful accounts: March 31, 2013 $846; and June 30, 2012 $887||95,904||74,744|
|Prepaid expenses and other current assets||3,068||2,231|
|Deferred income tax asset, net||1,260||948|
|Total current assets||228,486||191,969|
|Property and equipment, net||11,631||11,705|
|Property held for sale||4,058||3,752|
|Intangible assets, net||41,296||45,251|
|Deferred income tax asset, net||4,684||4,719|
|Total Assets||$ 333,282||$ 299,280|
|Liabilities and Shareholders' Equity|
|Current portion of long-term debt||$ 7,464||$ 6,713|
|Total current liabilities||91,160||73,641|
|Environmental remediation liability||6,370||5,633|
|Deferred income tax liability||20||8|
|Commitments and contingencies|
|Common stock, $.01 par value:|
|(40,000 shares authorized; 27,386 and 26,937 shares issued and outstanding at March 31, 2013 and June 30, 2012, respectively)||274||269|
|Capital in excess of par value||67,885||64,071|
|Accumulated other comprehensive income||2,252||1,319|
|Total shareholders' equity||185,169||168,003|
|Total liabilities and shareholders' equity||$ 333,282||$ 299,280|
|Diluted Net Income Per Common Share Excluding Charges (Non-GAAP Reconciliation)|
|(in thousands, except per share amounts)|
(unaudited) Three Months Ended March 31, 2013
Income Per Common Share Three Months Ended March 31, 2013
Three Months Ended March 31, 2012
Income Per Common Share Three Months Ended March 31, 2012
Nine Months Ended March 31, 2013
Income Per Common Share Nine Months Ended March 31,
Nine Months Ended March 31, 2012
Income Per Common Share Nine Months Ended March 31,
|Net income, as reported||$7,593||$ 0.28||$5,379||$ 0.20||$16,926||$ 0.62||$13,000||$ 0.49|
|Earn out costs||2,840||0.10||--||--||2,840||0.10|
|Adjusted income excluding charges||10,433||0.38||5,379||0.20||19,766||0.72||13,884||0.52|
|Adjustments to provision for income taxes||1,108||0.04||529||0.02||1,108||0.04||874||0.03|
|Adjusted net income (Non-GAAP)||$ 9,325||$ 0.34||$ 4,850||$ 0.18||$ 18,658||$ 0.68||$ 13,010||$ 0.49|
|Diluted weighted average shares outstanding||27,485||27,485||26,870||26,870||27,342||27,342||26,747||26,747|
|NOTE: Items identified in the above table are not in accordance with, or an alternative method for, generally accepted accounting principles (GAAP) in the United States. These items should not be reviewed in isolation or considered substitutes of the Company's financial results as reported in accordance with GAAP. Due to the nature of these items, it is important to identify these items and to review them in conjunction with the Company's financial results reported in accordance with GAAP. The exclusion of these items also allows investors to compare results of operations in the current period to prior period's results based on the Company's fundamental business performance and analyze the operating trends of the business. The exclusion of these items also allows management to evaluate performance of its business units.|
CONTACT: Investor Relations Contact: Stephanie Carrington The Ruth Group (646) 536-7017 firstname.lastname@example.org
- U.S.' Kerry expresses regret to India over diplomat case |
- Washington, DC city council raises minimum wage to $11.50/hr in 2016
- China confirms near miss with U.S. ship in South China Sea
- Mega Millions winners in Georgia, California to split $648 million |
- Medical bills underlie 60 percent of U.S. bankrupts: study